Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
Aspirin showed no clear difference in graft thrombosis (28 days to 18 months) compared with placebo (low certainty).
1 finding from 1 review
Fistula thrombosis (42 days to 6 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula
Clopidogrel showed no clear difference in fistula thrombosis (42 days to 6 months) compared with placebo (moderate certainty).
1 finding from 1 review
Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula
Clopidogrel showed no clear difference in number of related surgical or radiological interventions (42 days) compared with placebo (moderate certainty).
1 finding from 1 review
Complications (28 days to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft
1 finding from 1 review
Infants readmitted for neonatal morbidity within 28 days · healthy mothers and term infants
Early discharge probably leads to higher infants readmitted for neonatal morbidity within 28 days compared with standard discharge (moderate certainty).
1 finding from 1 review
Use of rescue medication · adults and children with chronic asthma
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ encephalitis meningitis ‐ encephalitis meningitis risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ encephalitis meningitis ‐ encephalitis… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ varicella zoster ‐ varicella zoster risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ varicella zoster ‐ varicella zoster… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ miscellaneous viral infections ‐ miscellaneous viral infections risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ miscellaneous viral infections ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Case‐control: MMR (risk interval from 0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in case‐control: MMR (risk interval from 0 to 90 days) (low certainty).
1 finding from 1 review
Intervention not reported
Case‐control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days · children 9 months to 15 years old
The intervention showed no clear difference in case‐control ‐ Jeryl Lynn ‐ risk interval 0 to 30 days (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR+V ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR+V ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention showed no clear difference in MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination (Priorix‐Tetra) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 7 to 10 days after vaccination… (low certainty).
1 finding from 1 review
Intervention not reported
MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) · children 9 months to 15 years old
The intervention may leads to higher MMRV vs MMR ‐ by brand ‐ from 0 to 42 days after vaccination (ProQuad) (low certainty).
1 finding from 1 review